FUROXONE
LOE ApproachingNDAORALTABLET
Approved
Mar 1961
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 7h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FUROXONE is an oral small-molecule tablet approved in 1961 by Takeda, representing a legacy NDA product. Mechanism of action and therapeutic indications are not currently documented in available data, limiting characterization of its clinical role.
LOE Approaching
Product approaching loss of exclusivity with low competitive pressure (30%), suggesting a contracting brand team and limited growth opportunity.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings and approaching LOE status indicate this is a maintenance-phase product with limited hiring and career growth potential. Roles focus on defending market share and managing generic transition rather than launching or expanding the franchise.
Brand ManagerField Sales Representative
Worked on FUROXONE at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.